Immunomedics Company Profile (NASDAQ:IMMU)

About Immunomedics (NASDAQ:IMMU)

Immunomedics logoImmunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. Its geographic segments include United States and Europe. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of eight clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:IMMU
  • CUSIP: 45290710
  • Web:
  • Market Cap: $1.28 billion
  • Outstanding Shares: 111,279,000
Average Prices:
  • 50 Day Moving Avg: $10.09
  • 200 Day Moving Avg: $7.94
  • 52 Week Range: $2.02 - $12.96
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -44.12
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $3.09 million
  • Price / Sales: 413.06
  • Book Value: ($0.53) per share
  • Price / Book: -21.64
  • EBIDTA: ($71,330,000.00)
  • Net Margins: -4,956.52%
  • Return on Assets: -109.37%
  • Debt-to-Equity Ratio: -1.65%
  • Current Ratio: 1.29%
  • Quick Ratio: 1.28%
  • Average Volume: 2.57 million shs.
  • Beta: 1.65
  • Short Ratio: 19.33

Frequently Asked Questions for Immunomedics (NASDAQ:IMMU)

What is Immunomedics' stock symbol?

Immunomedics trades on the NASDAQ under the ticker symbol "IMMU."

How were Immunomedics' earnings last quarter?

Immunomedics, Inc. (NASDAQ:IMMU) released its quarterly earnings data on Wednesday, August, 16th. The company reported ($0.25) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.12) by $0.13. The firm had revenue of $0.64 million for the quarter, compared to analysts' expectations of $0.75 million. Immunomedics's revenue for the quarter was down 31.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.17) EPS. View Immunomedics' Earnings History.

Where is Immunomedics' stock going? Where will Immunomedics' stock price be in 2017?

3 analysts have issued 12-month price objectives for Immunomedics' shares. Their predictions range from $14.00 to $15.00. On average, they expect Immunomedics' share price to reach $14.50 in the next twelve months. View Analyst Ratings for Immunomedics.

Are investors shorting Immunomedics?

Immunomedics saw a increase in short interest in August. As of August 31st, there was short interest totalling 34,287,202 shares, an increase of 0.6% from the August 15th total of 34,074,923 shares. Based on an average daily volume of 4,662,516 shares, the days-to-cover ratio is currently 7.4 days. Approximately 34.4% of the shares of the company are short sold.

Who are some of Immunomedics' key competitors?

Who are Immunomedics' key executives?

Immunomedics' management team includes the folowing people:

  • Jason M. Aryeh, Chairman of the Board
  • Cynthia L. Sullivan, President, Chief Executive Officer, Director
  • Michael R. Garone, Chief Financial Officer, Vice President - Finance
  • David M. Goldenberg, Chief Scientific Officer, Chief Patent Officer, Director
  • Geoffrey F. Cox Ph.D., Independent Director
  • Robert Forrester, Independent Director
  • Brian A. Markison, Lead Independent Director
  • Bob Oliver, Independent Director

Who owns Immunomedics stock?

Immunomedics' stock is owned by a number of of institutional and retail investors. Top institutional investors include FMR LLC (5.02%), State Street Corp (4.37%), Vanguard Group Inc. (4.13%), Farallon Capital Management LLC (3.83%), Palo Alto Investors LLC (2.73%) and First Light Asset Management LLC (1.86%). Company insiders that own Immunomedics stock include Cynthia L Goldenberg, David M Goldenberg, Don C Stark and Mary E Paetzold. View Institutional Ownership Trends for Immunomedics.

Who sold Immunomedics stock? Who is selling Immunomedics stock?

Immunomedics' stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Chicago Equity Partners LLC, Virtu KCG Holdings LLC, First Light Asset Management LLC, Atlantic Trust Group LLC, UBS Asset Management Americas Inc., IFP Advisors Inc and Swiss National Bank. Company insiders that have sold Immunomedics stock in the last year include Cynthia L Goldenberg and David M Goldenberg. View Insider Buying and Selling for Immunomedics.

Who bought Immunomedics stock? Who is buying Immunomedics stock?

Immunomedics' stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Palo Alto Investors LLC, State Street Corp, Lord Abbett & CO. LLC, Jennison Associates LLC, Goldman Sachs Group Inc., DAFNA Capital Management LLC and EAM Investors LLC. View Insider Buying and Selling for Immunomedics.

How do I buy Immunomedics stock?

Shares of Immunomedics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Immunomedics' stock price today?

One share of Immunomedics stock can currently be purchased for approximately $11.47.

MarketBeat Community Rating for Immunomedics (NASDAQ IMMU)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  145 (Vote Outperform)
Underperform Votes:  115 (Vote Underperform)
Total Votes:  260
MarketBeat's community ratings are surveys of what our community members think about Immunomedics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Immunomedics (NASDAQ:IMMU) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $14.50 (26.42% upside)

Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/19/2017Jefferies Group LLCBoost Price TargetBuy$11.00 -> $14.00HighView Rating Details
7/24/2017Cowen and CompanyReiterated RatingOutperform$15.00LowView Rating Details
5/5/2017Wells Fargo & CoUpgradeMarket Perform -> OutperformHighView Rating Details
(Data available from 9/25/2015 forward)


Earnings History for Immunomedics (NASDAQ:IMMU)
Earnings by Quarter for Immunomedics (NASDAQ:IMMU)
Earnings History by Quarter for Immunomedics (NASDAQ IMMU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/16/2017Q4 2017($0.12)($0.25)$0.75 million$0.64 millionViewN/AView Earnings Details
2/9/2017Q2 2017($0.13)($0.16)$0.70 million$0.38 millionViewListenView Earnings Details
11/2/2016Q117($0.14)($0.17)$0.70 million$0.74 millionViewN/AView Earnings Details
8/17/2016Q416($0.11)($0.17)$0.90 million$0.93 millionViewListenView Earnings Details
5/4/2016Q3($0.13)($0.15)$0.70 million$0.90 millionViewN/AView Earnings Details
2/3/2016Q216($0.14)($0.15)$1.40 million$0.67 millionViewN/AView Earnings Details
11/4/2015Q116($0.14)($0.16)$1.23 million$0.73 millionViewN/AView Earnings Details
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details
5/6/2015Q3 2015($0.13)($0.13)$1.07 million$1.18 millionViewN/AView Earnings Details
2/4/2015Q215($0.13)($0.12)$1.73 million$1.00 millionViewN/AView Earnings Details
11/5/2014Q1 2015($0.12)($0.13)$1.18 million$1.07 millionViewN/AView Earnings Details
8/25/2014Q414($0.13)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details
5/7/2014Q3 2014($0.12)$0.02$1.13 million$1.15 millionViewN/AView Earnings Details
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Immunomedics (NASDAQ:IMMU)
2017 EPS Consensus Estimate: ($0.53)
2018 EPS Consensus Estimate: ($0.56)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.12)($0.12)($0.12)
Q2 20171($0.15)($0.15)($0.15)
Q3 20171($0.15)($0.15)($0.15)
Q4 20171($0.11)($0.11)($0.11)
Q1 20181($0.11)($0.11)($0.11)
Q2 20181($0.12)($0.12)($0.12)
Q3 20181($0.14)($0.14)($0.14)
Q4 20181($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)


Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Immunomedics (NASDAQ:IMMU)
Insider Ownership Percentage: 6.60%
Institutional Ownership Percentage: 77.99%
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)
Insider Trades by Quarter for Immunomedics (NASDAQ:IMMU)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2017David M. GoldenbergInsiderSell20,000$12.64$252,800.00View SEC Filing  
8/28/2017Cynthia L. GoldenbergDirectorSell40,000$10.72$428,800.00View SEC Filing  
8/23/2017Cynthia L. GoldenbergDirectorSell40,000$9.24$369,600.00View SEC Filing  
8/24/2016Don C StarkDirectorSell9,900$2.97$29,403.00View SEC Filing  
8/23/2016Mary E PaetzoldDirectorSell15,000$2.98$44,700.00View SEC Filing  
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70View SEC Filing  
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42View SEC Filing  
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.80View SEC Filing  
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00View SEC Filing  
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.00View SEC Filing  
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31View SEC Filing  
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.98View SEC Filing  
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Immunomedics (NASDAQ:IMMU)
Latest Headlines for Immunomedics (NASDAQ:IMMU)
DateHeadline logoImmunomedics, Inc. (IMMU) Given New $14.00 Price Target at Jefferies Group LLC - September 24 at 1:00 PM logoForm 8-K IMMUNOMEDICS INC For: Sep 19 - - September 22 at 7:02 PM logoJefferies Group Research Analysts Reduce Earnings Estimates for Immunomedics, Inc. (IMMU) - September 21 at 11:20 AM logoImmunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock - September 16 at 1:40 AM logoImmunomedics (IMMU) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow - September 14 at 6:28 AM logoImmunomedics, Inc. (IMMU) Given Consensus Recommendation of "Buy" by Analysts - September 13 at 2:53 PM logoBRIEF-Immunomedics presents interim phase 2 results with sacituzumab govitecan (i - September 12 at 1:39 AM logoImmunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer - September 12 at 1:39 AM logoImmunomedics (IMMU) Reports Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) - - September 11 at 8:36 PM logoAre Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock? - Nasdaq - September 11 at 8:36 PM logoImmunomedics, Inc. (IMMU) Insider David M. Goldenberg Sells 20,000 Shares - September 5 at 10:26 PM logoIMMU Crosses Above Average Analyst Target - Nasdaq - September 1 at 8:13 PM logoImmunomedics to Participate in Upcoming Investor Conferences - August 31 at 6:10 AM logoImmunomedics Stock Breaks Out, Consolidation Likely - August 30 at 2:08 AM logoImmunomedics, Inc. (IMMU) Director Sells $428,800.00 in Stock - August 28 at 10:22 PM logoImmunomedics, Inc. (IMMU) Upgraded to Buy by BidaskClub - August 28 at 8:44 PM logoETFs with exposure to Immunomedics, Inc. : August 28, 2017 - August 28 at 7:28 PM logoHere's Why Immunomedics Rose as Much as 14.2% Today - August 28 at 4:58 PM logoMid-Day Market Update: Crude Oil Down 2.5%; MaxPoint Interactive Shares Spike Higher - August 28 at 12:52 PM logoImmunomedics, Inc. :IMMU-US: Earnings Analysis: Q4, 2017 By the Numbers : August 24, 2017 - August 25 at 7:05 AM logoMid-Afternoon Market Update: Crude Oil Down Over 2%; Abercrombie & Fitch Shares Surge Following Strong Q2 Results - August 24 at 3:10 PM logoForm 4 IMMUNOMEDICS INC For: Aug 21 Filed by: GOLDENBERG DAVID M - August 24 at 7:58 AM logoImmunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : August 22, 2017 - August 24 at 7:58 AM logoImmunomedics, Inc. (IMMU) Director Cynthia L. Goldenberg Sells 40,000 Shares - August 24 at 4:20 AM logoBRIEF-Immunomedics announces publication of cancer drug data - Reuters - August 22 at 12:05 AM logoResults Appeared in Advanced Online Publication of the American Society of Clinical Oncology Journal, Journal of Clinical Oncology - August 21 at 8:51 AM logoImmunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer - August 21 at 8:51 AM logoImmunomedics, Inc. Forecasted to Earn Q1 2018 Earnings of ($0.10) Per Share (IMMU) - August 21 at 6:22 AM logoImmunomedics, Inc. (IMMU) Given Consensus Rating of "Buy" by Analysts - August 19 at 12:52 PM logoFY2022 EPS Estimates for Immunomedics, Inc. Cut by Analyst (IMMU) - August 18 at 2:28 PM logoImmunomedics, Inc. (IMMU) PT Set at $11.00 by Jefferies Group LLC - August 18 at 11:22 AM logoImmunomedics, Inc. (IMMU) Releases Earnings Results, Misses Expectations By $0.13 EPS - August 17 at 9:20 AM logoBRIEF-Immunomedics reports Q4 loss per share $0.48 - August 17 at 5:54 AM logoEdited Transcript of IMMU earnings conference call or presentation 16-Aug-17 9:00pm GMT - August 17 at 5:54 AM logoImmunomedics' (IMMU) Q4 2017 Results - Earnings Call Transcript - Seeking Alpha - August 17 at 12:52 AM logoImmunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : August 17, 2017 - August 17 at 12:52 AM logoAfter-Hours Earnings Report for August 16, 2017 : CSCO, NTAP, LB, VIPS, CACI, BGG, SPTN, IMMU, GPRK, PBIO - Nasdaq - August 16 at 7:49 PM logoImmunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission ... - GlobeNewswire (press release) - August 16 at 7:49 PM logoImmunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline - August 16 at 7:49 PM logoImmunomedics reports 4Q loss - August 16 at 7:49 PM logoZacks Investment Research Lowers Immunomedics, Inc. (IMMU) to Hold - August 11 at 12:28 AM logoImmunomedics Announces Conference Call and Webcast for Fourth Quarter and Fiscal Year 2017 Results - August 7 at 7:15 PM logoImmunomedics, Inc. (IMMU) Stock Rating Lowered by BidaskClub - August 4 at 11:52 PM logoBRIEF-Immunomedics, Covance enter into master services agreement - August 4 at 8:07 PM logoImmunomedics, Inc. breached its 50 day moving average in a Bearish Manner : IMMU-US : August 3, 2017 - August 3 at 7:57 PM logoImmunomedics, Inc. (IMMU) Receives Consensus Recommendation of "Buy" from Brokerages - July 25 at 3:07 PM logoCowen and Company Reaffirms Outperform Rating for Immunomedics, Inc. (NASDAQ:IMMU) - July 24 at 4:10 PM logoImmunomedics, Inc. (IMMU) Raised to "Buy" at Zacks Investment Research - July 18 at 12:56 AM logoFY2019 Earnings Forecast for Immunomedics, Inc. (NASDAQ:IMMU) Issued By Jefferies Group - July 17 at 11:11 AM logoJefferies Group LLC Reaffirms "Buy" Rating for Immunomedics, Inc. (IMMU) - July 15 at 4:12 PM



Immunomedics (IMMU) Chart for Monday, September, 25, 2017

This page was last updated on 9/25/2017 by Staff